May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Management Patterns of Glaucoma Treatment in the Thessaloniki Eye Study (TES)
Author Affiliations & Notes
  • F. Topouzis
    II Department of Ophthalmology, Aristotle Univ of Thessaloniki, Thessaloniki, Greece
  • A. L. Coleman
    Center for Eye Epidemiology, University of California Los Angeles, Los Angeles, California
  • A. Harris
    Ophthalmology, Indiana University, Indianapolis, Indiana
  • F. Yu
    Center for Eye Epidemiology, University of California Los Angeles, Los Angeles, California
  • E. Anastasopoulos
    II Department of Ophthalmology, Aristotle Univ of Thessaloniki, Thessaloniki, Greece
  • T. Pappas
    II Department of Ophthalmology, Aristotle Univ of Thessaloniki, Thessaloniki, Greece
  • A. Koskosas
    II Department of Ophthalmology, Aristotle Univ of Thessaloniki, Thessaloniki, Greece
  • P. Founti
    II Department of Ophthalmology, Aristotle Univ of Thessaloniki, Thessaloniki, Greece
  • M. R. Wilson
    School of Medicine, University of Colorado and Health Sciences Center, Denver, Colorado
  • Footnotes
    Commercial Relationships  F. Topouzis, None; A.L. Coleman, None; A. Harris, None; F. Yu, None; E. Anastasopoulos, None; T. Pappas, None; A. Koskosas, None; P. Founti, None; M.R. Wilson, None.
  • Footnotes
    Support  International Glaucoma Association, Center for Eye Epidemiology, UCLA, Health Future Foundation, Creighton University,Pfizer, Inc., New York, NY, Glaucoma Research & Education Foundation, Indianapoli
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3604. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Topouzis, A. L. Coleman, A. Harris, F. Yu, E. Anastasopoulos, T. Pappas, A. Koskosas, P. Founti, M. R. Wilson; Management Patterns of Glaucoma Treatment in the Thessaloniki Eye Study (TES). Invest. Ophthalmol. Vis. Sci. 2008;49(13):3604. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the patterns of glaucoma treatment in open-angle glaucoma (OAG) patients and OAG suspects in a population-based sample of subjects 60 years of age or older in Thessaloniki, Greece.

Methods: : A total of 2554 subjects randomly identified from municipality registers in Thessaloniki were interviewed with a questionnaire and underwent a complete ophthalmologic examination. Participants were classified as OAG (either primary open-angle glaucoma (POAG) or pseudoexfoliative glaucoma (PEXG)) and OAG suspects according to specific criteria. Distribution of glaucoma medications use and the proportion using monotherapy among OAG patients and OAG suspects were assessed. Comparisons among OAG patients and OAG suspects were based on Fisher exact tests.

Results: : There were 141 OAG (98 POAG/43 PEXG) subjects identified in TES. Of those with OAG, 50.4% were previously undiagnosed. Of OAG subjects, 40.4% were receiving glaucoma medications and 11% of OAG had prior glaucoma surgery including laser.Among the 2261 clinic-visit participants, there were 52 OAG patients and 45 OAG suspects receiving glaucoma medications. 78% of OAG suspects used b-blockers compared to 58% of OAG subjects (p=0.05), while 33% of OAG suspects used prostaglandin analogues compared to 65% of OAG subjects (p=0.002). OAG subjects were also more likely to use carbonic anhydrase inhibitors (11% vs 42%, p<0.001) and alpha 2-agonists (2.2% vs. 17%, p=0.018) than OAG suspects. 25/52 (48%) OAG subjects and 33/45 (73%) OAG suspects were on glaucoma monotherapy (p=0.014). Among those receiving monotherapy, indicating first choice glaucoma treatment preference, 76% of OAG suspects used b-blockers compared to 28% of OAG subjects (p<0.001), while 21% of OAG suspects used prostaglandin analogues compared to 56% of OAG subjects (p=0.012).

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×